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The aim of this study was to evaluate the efficacy and tolerability of gefitinib (‘IRESSA’) in Japanese patients with previously untreated
stage IV non-small-cell lung cancer (NSCLC). This was a multi-institutional phase II study. Thirty-four patients with previously
untreated stage IV NSCLC were enrolled between May 2003 and September 2004. Gefitinib was administered orally 250mg once a
day and was continued until there was either disease progression or severe toxicity. Objective tumour response rate was 26.5% (95%
confidence interval, 11.7–41.3%). Adverse events were generally mild (National Cancer Institute-Common Toxicity Criteria grade 1
or 2) and consisted mainly of skin rash, fatigue and liver dysfunction. No pulmonary toxicity was observed. The global health status
revealed that there was no change in quality of life during the study. This study found that single-agent gefitinib is active and well
tolerated in chemonaive Japanese patients with advanced NSCLC.
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Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine
kinase (TK) inhibitor that blocks signal pathways involved in
proliferation and survival of cancer cells (Wakeling et al, 1996). A
phase I clinical trial showed that gefitinib is well tolerated and
active in solid, malignant tumours (Ranson et al, 2002). Two large
randomised phase II studies in patients with non-small-cell lung
cancer (NSCLC) who had progressive disease (PD) following
platinum-based chemotherapy, IRESSA Dose Evaluation in Ad-
vanced Lung Cancer (IDEAL 1) and 2 demonstrated response rates
of 12–18%. (Fukuoka et al, 2003; Kris et al, 2003). A higher
response rate of 28% was observed in Japanese patients in IDEAL
1, which is comparable to the response rate of 19% shown in the
ECOG randomised study of four platinum-based chemotherapy
regimens (Schiller et al, 2002). Gefitinib showed encouraging
response rate (23%, 5 out of 22) and survival benefit (median
survival 12.6 months) as a first-line therapy in NSCLC in the
compassionate use (Argiris and Mittal, 2004) and a response rate
of 27% (10 out of 37) in Japanese chemonaive patients with
advanced NSCLC (Niho et al, 2004). The adverse effects of gefitinib
were generally mild such as skin eruption, diarrhoea and nausea.
These data suggest that further clinical evaluation of gefitinib in
Japanese chemonaive patients is warranted. Therefore, we
evaluated the efficacy and tolerability of gefitinib as a first-line
therapy in a Japanese patient population. When disease progres-
sion was observed, the standard platinum-based doublet che-
motherapy was considered to use as salvage.
MATERIALS AND METHODS
Patients
This study began in May 2003 and ended in September 2004.
Patients inclusion criteria were as follows: (1) Stage IV NSCLC
without previous chemotherapy or radiotherapy; (2) patients who
had measurable lesions; (3) patients whose ages were 20pageo75;
(4) patients whose Eastern Cooperative Oncology Group-Perfor-
mance Status (ECOG-PS) were 0 or 1; (5) patients who had
adequate organ function; partial pressure of oxygen in arterial
blood (PaO2) X70Torr, adequate bone marrow (absolute neu-
trophil count X1500mm
 3, platelets X100000mm
 3, haemoglo-
bin X10gdl
 1), renal function (serum creatinine p1.25 upper
normal limit) and hepatic function (serum glutamic–oxaloacetic
transaminase and serum glutamic pyruvic transaminase
p1.25 upper normal limit). All patients with interstitial pneu-
monia were strictly excluded by chest computed tomography (CT).
All patients gave written informed consent before enrollment.
This protocol was approved by the Institutional Review Boards of
the participating centres.
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Patients received gefitinib 250mg orally, once a day. Study
treatment was continued until disease progression or severe
toxicity. In these cases, patients received carboplatin (CBDCA) and
paclitaxel (TXL) chemotherapy as second-line therapy. Patients
received TXL 200mgm
 2 as a 1-h intravenous infusion, followed
by CBDCA area under the curve (AUC) 6.0 (Calvert’s setting) as a
1-h infusion on day 1. Courses of treatment were repeated every 3
or 4 weeks depending on the recovery of toxicity.
Tumour response was assessed as complete response (CR),
partial response (PR), stable disease ^12 weeks (SD), or PD in
accordance with the standard Response Evaluation Criteria In
Solid Tumours (RECIST). Toxicity was evaluated using National
Cancer Institute-Common Toxicity Criteria (NCI-CTC) (version
2). Quality of life (QOL) was evaluated before the start of therapy
and at 4 and 12 weeks, using the European Organisation for
Research and Treatment of Cancer Care Quality of Life Ques-
tionnaire (EORTC-QLQ-C30) and lung-cancer-specific module
(LC13) (Aaronson et al, 1993).
Statistical considerations
The primary end point was response rate. The secondary end
points were toxicity, survival from the date of enrolment and QOL.
According to Simon’s minimax two-stage phase II study design,
the treatment programme was designed for a minimal response
rate of 15% and to provide a significance level of 0.10 with a
statistical power of 80% in assessing the activity of the regimen
according to a 35% response rate. The upper limit for first-stage
drug rejection was two responses in 17 evaluable patients. The
upper limit for second-stage drug rejection was nine responses in
32 evaluable patients. We chose a sample number of 34, to allow
for two dropouts. Tumour responses in subsets were compared
using Fisher’s exact test. Quality-of-life analyses were performed
using Wilcoxon’s signed-rank test. All P-values were considered
significant if p0.05.
RESULTS
Patient characteristics and treatment administration
Thirty-four patients were enrolled and all of them were eligible.
Patient characteristics are shown in Table 1. Of the 34 patients, 21
were men and 13 were women. Median age was 64 years (range:
43–73). The ECOG-PS was 0 in 16 patients and 1 in 18 patients.
The predominant histology was adenocarcinoma (25 patients).
Twenty-three patients had smoking history (including current
smoker or ex-smoker). Of the 34 patients, 33 patients discontinued
gefitinib treatment. The reasons for discontinuing treatment were
progression of disease (n¼30), toxicities (skin; n¼1, liver; n¼1)
and patient request (n¼1). The median treatment period was 2.4
months (range: 1–23 months). Only one patient is still receiving
treatment with gefitinib.
Response
Nine patients (26.5%) achieved PR, and eight patients (23.5%) had
SD as their best response. The objective response rate was 26.5%
(95% CI, 11.7–41.3%). Subset analysis is shown in Table 2. Seven
out of the 13 female patients achieved PR. There was a statistically
significant difference between men and women. However, other
factors such as pathology, smoking history and ECOG-PS
demonstrated no significant difference. Median duration of
response was 8.8 months (range 2.1–22.0 months). Median
follow-up was 15.8 months (range 2.9–33.8 months).
Overall survival
Median survival time was 14.1 months. The 1-year survival rate
was 58.2%. Twenty-one patients died during the study period, and
13 patients are still alive. The Kaplan–Meier survival curve is
shown in Figure 1.
Toxicities
Thirty-three patients were evaluated for toxicity. One patient
demonstrated liver dysfunction from disease progression within 1
week of enrolling and was not evaluated for toxicity assessment.
Generally, toxicities were mild. The most common toxicities were
skin rash, general fatigue and liver dysfunction (Table 3). Most were
grade 1 or 2 in severity and four patients (11.8%) experienced grade 3
toxicities (one skin rash, one general fatigue and four liver
dysfunction). There was no pulmonary toxicity during the treatment.
Quality of life
The global health status revealed no significant differences between
QOL before gefitinib therapy and 4 or 12 weeks after commencing
therapy, compared to baseline. Quality of life-30 scores were
4.771.7 before therapy, 4.971.3 after 4 weeks and 4.971.1 after
12 weeks (Table 4). For the other scales, at 12 weeks, improvement
of insomnia and constipation, worsening of appetite loss,
diarrhoea, financial difficulties and alopecia were observed (Tables
4 and 5).
Table 1 Patient characteristics
Sex Male/female 21/13
Age Median (range) 64 (43–73)
ECOG-PS 0/1 16/18
Histology Ad/Sq/Other 25/5/4
Smoking history Yes/never 23/11
Clinical stage Stage IV 34
Ad¼adenocarcinoma; Sq¼squamous-cell carcinoma; ECOG-PS¼Eastern Coop-
erative Oncology Group Performance Status.
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Figure 1 Kaplan–Meier survival curve.
Table 2 Subset analysis (response rate)
Patient characteristics Response rate P-value
Sex Male vs female 2/21 (9.5%) vs 7/13 (53.8%) 0.0057
Pathology Ad vs Sq+other 7/25 (28%) vs 2/9 (22.2%) 0.7432
Smoking Current+ex-smoker vs
never smoker
4/23 (17.4%) vs 5/11 (45.5%) 0.1009
ECOG-PS 0 vs 1 5/16 (31.3%) vs 4/18 (22.2%) 0.5633
Ad¼adenocarcinoma; Sq¼squamous-cell carcinoma; ECOG-PS¼Eastern Coop-
erative Oncology Group Performance Status.
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In total, 19 patients received second-line chemotherapy
(CBDCAþTXL) subsequent to gefitinib. One had a CR, five had
PR, nine had SD, and four had PD. Overall response rate was 31.6%
(6 out of 19); 95% CI was 10.7–52.5%. The reasons of the 14
patients (one patients is still receiving gefitinib) who have not
received the subsequent chemotherapy were patient’s rejection to
chemotherapy treatment (n¼8), patient’s request for other
regimens (n¼3) and worsening of general condition (n¼3).
DISCUSSION
Lung cancer is a major cause of cancer death in many countries in
the world (Greenlee et al, 2000). Despite advances in treatment, a
large meta-analysis of randomised trials demonstrated insufficient
outcome of a 1-year survival benefit of 10% and a modest
improvement in the median survival of 1.5 months for patients
who were treated with platinum-containing regimens, compared
with best supportive care (Non-small Cell Lung Cancer Collabora-
tive Group, 1995). In addition, severe toxicities associated with
platinum-based chemotherapy often led to treatment discontinua-
tion. Therefore new drugs with novel modes of action that are
effective and have less toxicities are needed. Gefitinib is a targeted
drug with single-agent activity, and has shown mild toxicity in
platina pretreated patients with NSCLC (Fukuoka et al, 2003; Kris
et al, 2003).
As first-line therapy, gefitinib has been assessed in combination
with two different chemotherapy regimens in two large rando-
mised studies (IRESSA NSCLC Trial Assessing Combination
Treatment (INTACT) 1 and INTACT 2) (Giaccone et al, 2004;
Herbst et al, 2004). Disappointingly, both studies failed to show an
improvement in either survival or other clinical end points.
A large placebo-controlled phase III study in patients with
advanced NSCLC who had received one or two prior chemother-
apy regimens, IRESSA Survival Evaluation in Lung Cancer (ISEL),
showed some improvement in overall survival with single-agent
gefitinib that failed to reach statistical significance compared with
placebo in the overall or adenocarcinoma co-primary populations.
However, there was marked heterogeneity in survival outcomes
between patient groups, with some evidence of benefit among
never-smokers and patients of Asian origin (Thatcher et al, 2005).
Little information is available for single-agent gefitinib as first-
line therapy, and the available data are from compassionate use of
gefitinib with a small number of patients (Argiris and Mittal, 2004;
Niho et al, 2004).
In the present study, the overall response rate was 26.5%. We
demonstrated that gefitinib was active in patients with NSCLC as
first-line single-agent therapy. It has been reported that gefitinib is
more effective in women, in nonsmokers, in patients affected with
adenocarcinoma and in patients of East Asian ethnicity (Fukuoka
et al, 2003; Kris et al, 2003; Miller et al, 2004; Ho et al, 2005). As all
of our patients were Japanese, it is not surprising that this response
rate is higher than would be expected in other ethnicities (Argiris
and Mittal, 2004; Kommareddy et al, 2004). In our subset analysis,
women had a higher response rate than men (53.8 vs 9.5%).
However, other predicting factors such as smoking history or
histology did not show any significant differences, possibly due to
the small sample size.
Mutations in the TK domain of the EGFR have been identified in
some patients with refractory NSCLC who achieved good
responses to gefitinib (Cappuzzo et al, 2004; Lynch et al, 2004;
Pao et al, 2004). Further recent studies suggest that the mutation
status of EGFR-TK may predict clinical benefits with gefitinib
(Marchetti et al, 2005; Mitsudomi et al, 2005; Yang et al, 2005).
Different efficacy in different ethnicities may be explained by the
different frequency of these mutations in different ethnic groups.
Table 3 Toxicities (NCI-CTC version 2.0)
No. of patients
Grade 1 2 3 Total
Skin rash 14 5 1 20
General fatigue 6 3 1 10
Liver dysfunction 2 4 4 10
Diarrhoea 6 0 0 6
Nausea 4 2 0 6
Anaemia 0 1 0 1
NCI-CTC¼National Cancer Institute-Common Toxicity Criteria. There were no
pulmonary toxicities.
Table 4 Evaluation of the quality of life of patients using the QLQ-C30
questionnaire
Before therapy
n¼34
After 4 weeks
n¼32
After 12 weeks
n¼20
Global health
status/QOL
4.771.7 4.971.3 4.971.1
Functional scales
Physical
functioning
94.077.2 94.677.0 93.376.4
Role functioning 94.6713.2 96.277.1 93.178.6
Emotional
functioning
82.8719.7 86.6713.6 86.8713.5
Cognitive
functioning
85.5715.4 86.6714.5 87.5714.4
Social functioning 73.7726.8 79.6721.4 81.9723.0
Role functioning 94.6713.2 96.277.1 93.178.6
Symptom scales/items
Fatigue 19.4717.0 23.7721.0 19.4714.3
Nausea and
vomiting
0.573.0 1.675.0 2.876.5
Pain 18.3717.4 14.5713.4 15.3716.6
Dyspnoea 15.1718.9 19.4724.0 13.9717.2
Insomnia 30.1730.3* 14.0718.8* 11.1716.4*
Appetitie loss 9.7715.4 18.3724.0* 22.2729.6*
Constipation 14.0718.8 15.1722.5 0*
Diarrhoea 5.4712.5 12.9718.6 25.0732.2*
Financial
difficulties
21.5731.7 21.5728.0 30.6738.8*
QLQ-C30¼Quality of Life Questionnaire; QOL¼quality of life. *Po0.05
compared with before therapy.
Table 5 QOL evaluation (LC13)
Before therapy
n¼34
After 4
weeks n¼32
After 12
weeks n¼20
Symptom scales/items
Dyspnoea 12.5717.1 14.0717.7 11.1716.4
Coughing 32.3715.8 24.7721.0 22.2716.4
Haemoptysis 4.2711.2 8.6717.1 8.3715.1
Sore mouth 6.379.9 9.7717.6 5.6713.0
Dysphagia 3.179.9 6.5715.9 11.1716.4
Peripheral neuropathy 15.6717.2 14.0718.8 13.9717.2
Alopecia 3.1713.0 7.5718.7 16.7717.4*
Chest pain 10.4715.7 7.5714.2 13.9717.2
Arm or shoulder pain 7.3718.4 10.8718.0 19.4733.2
Pain in other regions 26.9727.8 18.3720.8 16.7717.4
QOL¼quality of life; LC13¼lung-cancer-specific module. *Po0.05 compared with
before therapy.
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therapy of advanced lung cancer. It was reported that an
improvement in QOL was observed in a gefitinib compassionate-
use programme (Mu et al, 2004). In the present study, global health
status did not change during gefitinib therapy. At 12 weeks of
gefitinib therapy, improvement of insomnia and constipation, but
worsening of appetite loss, diarrhoea, financial difficulties and
alopecia were observed. Treatment with single-agent gefitinib
therapy did not result in worsening of symptoms such as fatigue,
nausea and vomiting.
Recently, concerns have arisen about an infrequent but serious
side effect of gefitinib – interstitial pneumonia. A large randomised
phase II study (IDEAL 1; Fukuoka et al, 2003) reported only two
interstitial pneumonia cases out of 210 patients owing to gefitinib,
and these cases were at a 500-mg dose of gefitinib. However, a
surprisingly high incident rate of interstitial pneumonia (four of 18
patients) was reported from Japan (Inoue et al, 2003). Indeed, in a
phase II study from Japan, four patients out of 42 patients
developed grade 5 interstitial pneumonia (Niho et al, 2004). The
incidence of pulmonary toxicity is thought to be higher in Japanese
than in other ethnicities (FDA, 2003). Furthermore, it has been
reported that the incidence of interstitial lung disease (ILD) in the
Japanese patients on gefitinib was 4.5%, and it was higher in
the patients with pre-existing pulmonary fibrosis (Hotta et al,
2005). Furthermore, many chemotherapeutic agents have
ILD information and precautions documented within their
Japanese prescribing information. Reasons for the difference in
reporting rate between Japan and the rest of world are unknown
and require further scientific investigation. In the present study,
we strictly excluded patients who had pulmonary fibrosis by chest
CT, and no pulmonary toxicity occurred. Thus, in East Asia,
patients should be very carefully selected and observed during
gefitinib therapy.
In our study, the median survival time was 14.1 months, and the
1-year survival rate was 58.2%. Common toxicities were skin rash,
general fatigue and liver dysfunction. However, there was no
significant haematological or pulmonary toxicity. Gefitinib showed
antitumour activity, even in stage IV NSCLC, with a good survival
outcome.
In conclusion, phase III studies are warranted to compare
platinum-containing regimens vs gefitinib alone in the East Asian
population.
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